Demonstration of Remote Surgery Using the hinotori™ Surgical Robot System Successfully Performed Between Singapore and Japan

Medicaroid Corporation succeeded in a demonstration of remote surgery between Singapore and Japan’s Aichi prefecture (5,000 km apart) by the hinotori Surgical Robot System. This was Japan’s first remote surgery demonstration conducted between Singapore and Japan.

AlliedCel, a Joint Venture Between Sysmex and JCR Pharmaceuticals, Has Acquired a New Pipeline to Promote the Early Social Implementation of Regenerative Medicine Products - Securing the Manufacturing and Sales License for Regenerative Medicine Products Developed by JUNTEN BIO -

Sysmex Corporation announces that AlliedCel Corporation, a joint venture with JCR Pharmaceuticals Co., Ltd. has entered into a license agreement with JUNTEN BIO Co., Ltd. to play roles in the domestic manufacturing and sales of regenerative medicine products for immune tolerance induction with inducible inhibitory T-cells (JB-101).

VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600 million Japanese yen (approximately $4 million USD) through Third-Party Allotment. Cumulative Funds Raised Amount to Approximately 1.7 billion yen (Approximately $11.3 million USD)

VCCT Inc.(President: Masayo Takahashi) is pleased to announce the completion of a private equity allotment of approximately 600 million yen ($4 million USD). The allotment involved new shares to Sysmex Corporation (President: Kaoru Asano), DAI-DAN CO., LTD. (Representative Director, President: Ichiro Fujisawa), and YASKAWA Electric Corporation (Representative Director, President: Masahiro Ogawa). VCCT will continue to accelerate the development of retinal regenerative medicine together with these partners.